Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer

Open access

Abstract

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Genetic polymorphisms in tumour suppressor genes and genes encoding xenobiotic metabolising enzymes alter the activity of their corresponding enzymes and are important individual susceptibility factors for NSCLC. Because of the lack of information in literature, the aim of our study was to investigate the role of the tumour suppressor gene TP53 (Arg72Pro) and the xenobiotic metabolising CYP2E1*5B gene polymorphisms on the risk of NSCLC development. The study population consisted of 172 patients and 172 controls (156 men and 16 women in each group). Genetic polymorphisms were determined with real-time polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (PCR-RFLP). Multivariate analysis showed a significant association with NSCLC for the combination between the TP53 codon72 Arg/Pro and the Pro/Pro genotypes (OR 2.21, 95 % CI 1.390-3.51; p=0.001). We also analysed whether combinations of these gene variants with GSTM1, GSTT1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) gene polymorphisms were associated with the NSCLC risk. A significant increase in the risk was observed for the following combinations: TP53 codon72 variant with GSTM1 null (OR 2.22, 95 % CI 1.23-4.04; p=0.009), GSTT1 null (OR 2.98, 95 % CI 1.49-5.94; p=0.002), and GSTP1 (Ala114Val) variant genotypes (OR 3.38, 95 % CI 1.54-7.41; p=0.002). Further studies with larger samples are needed to verify these findings.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. World Health Organization. Cancer. Fact Sheet No 297 February 2015[displayed 17 November 2016]. Available at http://www.who.int/mediacentre/factsheets/fs297/en/

  • 2. Gresner P Gromadzinska J Wasowicz W. Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer. Lung Cancer 2007;57:1-25. doi:

    • Crossref
    • Export Citation
  • 3. Vineis P Anttila S Benhamou S Spinola M Hirvonen A Kiyohara C Garte SJ Puntoni R Rannug A Strange RC Taioli E. Evidence of gene-gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis 2007;28:1902-5. doi:

    • Crossref
    • Export Citation
  • 4. Hrstka R Coates PJ Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009;13:440-53. doi:

    • Crossref
    • Export Citation
  • 5. Thomas M Kalita A Labrecque S Pim D Banks L Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100. doi:

    • Crossref
    • Export Citation
  • 6. Dumont P Leu JI Della Pietra AC III George DL Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65. doi:

    • Crossref
    • Export Citation
  • 7. Qiao Q Hu W. The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30038 subjects. Lung 2013;191:369-77. doi:

    • Crossref
    • Export Citation
  • 8. Ye XH Bu ZB Feng J Peng L Liao XB Zhu XL Sun XL Yu HG Yan DF Yan SX. Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep 2014;41:373-85. doi:

    • Crossref
    • Export Citation
  • 9. Zhang H Hao S Zhao J Zhou B Ren Y Yan Y Zhao Y. Common genetic variants in 53BP1 associated with nonsmall-cell lung cancer risk in Han Chinese. Arch Med Res 2014;45:84-9. doi:

    • Crossref
    • Export Citation
  • 10. Wang X Hao LR Yue K. The TP53 codon 72 Pro/Pro genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis. Int J Clin Exp Med 2015;8:3120-6. PMID: 26064201

  • 11. Chowdhury MK Moniruzzaman M Emran AA Mostafa MG Kuddus RH Uddin MA. TP53 codon 72 polymorphisms and lung cancer risk in the Bangladeshi population. Asian Pac J Cancer Prev 2015;16:3493-8. doi:

    • Crossref
    • Export Citation
  • 12. Guengerich FP Kim DH Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-79. doi:

    • Crossref
    • Export Citation
  • 13. Oyama T Sugio K Uramoto H Iwata T Onitsuka T Isse T Nozoe T Kagawa N Yasumoto K Kawamoto T. Increased cytochrome P450 and aryl hydrocarbon receptor in bronchial epithelium of heavy smokers with non-small cell lung carcinoma carries a poor prognosis. Front Biosci 2007;12:4497-503. PMID: 17485391

  • 14. Watanabe J Hayashi S Nakachi K Imai K Suda Y Sekine T Kawajiri K. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 1990;18:7194. PMID: 1979861

  • 15. Hayashi S Watanabe J Kawajiri K. Genetic polymorphisms in the 5’-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-65. PMID: 1778977

  • 16. Liu G Miller DP Zhou W Thurston SW Fan R Xu LL Lynch TJ Wain JC Su L Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 2001;61:8718-22. PMID: 11751390

  • 17. Gaspar P Moreira J Kvitko K Torres M Moreira A Weimer T. CYP1A1 CYP2E1 GSTM1 GSTT1 GSTP1 and TP53 polymorphisms: do they indicate susceptibility to chronic obstructive pulmonary disease and non-small-cell lung cancer? Genet Mol Biol 2004;27:133-8. doi:

    • Crossref
    • Export Citation
  • 18. Tan C Xu HY Zhang CY Zhang H Chen CM Zhang WM Sun XY Jin YT. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer. Arch Med Res 2011;42:669-76. doi:

    • Crossref
    • Export Citation
  • 19. Ada AO Kunak SC Hancer F Soydas E Alpar S Gulhan M Iscan M. Association between GSTM1 GSTT1 and GSTP1 polymorphisms and lung cancer risk in a Turkish population. Mol Biol Rep 2012;39:5985-93. doi:

    • Crossref
    • Export Citation
  • 20. World Health Organization. Histological typing of lung tumours. Tumori 1981;67:253-72. [No authors listed] PMID: 6274068

  • 21. Talseth BA Meldrum C Suchy J Kurzawski G Lubinski J Scott RJ. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer 2006;118:2479-84. doi:

    • Crossref
    • Export Citation
  • 22. Choi JY Abel J Neuhaus T Ko Y Harth V Hamajima N Tajima K Yoo KY Park SK Noh DY Han W Choe KJ Ahn SH Kim SU Hirvonen A Kang D. Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development. Pharmacogenetics 2003;13:67-72. DOI: 10.1097/01.fpc.0000054060.98065.fc

  • 23. Liu G Miller DP Zhou W Thurston SW Fan R Xu LL Lynch TJ Wain JC Su L Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 2001;61:8718-22. PONOVLJENA REF. 16.

  • 24. Yang S Guo H Wei B Zhu S Cai Y Jiang P Tang J. Association of miR-502-binding site single nucleotide polymorphism in the 3’-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. Acta Biochim Biophys Sin (Shanghai) 2014;46:149-54. doi:

    • Crossref
    • Export Citation
  • 25. Loginov VI Atkarskaia MV Burdennyĭ AM Zavarykina TM Kazubskaia TP Nosikov VV Braga ÉA Zhizhina GP. Association of Arg72Pro of TP53 and T309g of MDM2 genes with non-small-cell lung cancer in Russians of Moscow region. Mol Biol 2014;48:52-7. doi:

    • Crossref
    • Export Citation
  • 26. Szymanowska A Jassem E Dziadziuszko R Borg A Limon J Kobierska-Gulida G Rzyman W Jassem J. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 2006;52:9-14. doi:

    • Crossref
    • Export Citation
  • 27. Fernández-Rubio A López-Cima MF González-Arriaga P García-Castro L Pascual T Marrón MG Tardón A. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer 2008;61:309-16. doi:

    • Crossref
    • Export Citation
  • 28. Wang Y Yang H Li L Wang H Zhang C Yin G Zhu B. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer 2010;46:758-64. doi:

    • Crossref
    • Export Citation
  • 29. Zhan P Wang J Zhang Y Qiu LX Zhao SF Qian Q Wei SZ Yu LK Song Y. CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians. Lung Cancer 2010;69:19-25. doi:

    • Crossref
    • Export Citation
  • 30. Zienolddiny S Campa D Lind H Ryberg D Skaug V Stangeland LB Canzian F Haugen A. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008;29:1164-9. doi:

    • Crossref
    • Export Citation
  • 31. Li W Yue W Zhang L Zhao X Ma L Yang X Zhang C Wang Y Gu M. Polymorphisms in GSTM1 CYP1A1 CYP2E1 and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung 2012;190:91-8. doi:

    • Crossref
    • Export Citation
  • 32. Cao L Lin J He B Wang H Rao J Liu Y Zhang X. A regulatory variant in CYP2E1 affects the risk of lung squamous cell carcinoma. Tumor Biol 2014;35:455-62. doi:

    • Crossref
    • Export Citation
  • 33. Klinchid J Chewaskulyoung B Saeteng S Lertprasertsuke N Kasinrerk W Cressey R. Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genet Cytogenet 2009;195:143-9. doi:

    • Crossref
    • Export Citation
Search
Journal information
Impact Factor

IMPACT FACTOR 2018: 1.436
5-year IMPACT FACTOR: 1.606

CiteScore 2018: 1.53

SCImago Journal Rank (SJR) 2018: 0.358
Source Normalized Impact per Paper (SNIP) 2018: 0.608

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 185 109 7
PDF Downloads 89 56 3